The BioMart Community Portal ( www.biomart.org ) is a community-driven effort to provide a
unified interface to biomedical databases that are distributed worldwide. The portal provides …

Background Patients who have unresectable or metastatic melanoma with a BRAF V600E
or V600K mutation have prolonged progression-free survival and overall survival when …

… free survival, overall survival, and distant metastasis–free survival than placebo. There were
more immune-related adverse events with ipilimumab than with placebo. (Funded by Bristol-…

… Pembrolizumab has been found to be associated with longer progression-free survival and
… over placebo with regard to recurrence-free survival in resected stage III melanoma, and a …

… , improves the progression-free and overall survival of patients who … , resulting in a median
progression-free survival of 6 to 7 … The median progression-free survival was 9.4 months with …

… The median progression-free survival was not reached with the combination therapy and …
Similar results for response rate and progression-free survival were observed in 33 patients …

… At a median follow-up of 2.8 years, the estimated 3-year rate of relapse-free survival was 58%
… Rates of distant metastasis–free survival and freedom from relapse were also higher in the …

… Therefore, we chose progression-free survival as the primary end point, with the opportunity
for patients with disease progression while receiving chemotherapy to cross over to receive …

… Coprimary end points were rates of overall and progression-free survival. Secondary end
points included the response rate, response duration, and safety. A final analysis was planned …

… We compared the recurrence-free survival distributions of the treatment groups with a log-rank
test at a two-sided alpha level of 0·05, stratified by stage as indicated at randomisation. …